Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

CANG vs YI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CANG Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–6 Matrix Metrics)

CANG Overall Winner 6-Pillar Tally: CANG 3 – 2 YI (1 Tie) Matrix Metrics: CANG 4 – 6 YI

As of Nov 19, 2026, Cango Inc. (CANG) is the stronger overall head-to-head candidate over 111, Inc. (YI) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). CANG carries a Unified Composite Score of 51.3/100 (HOLD) at $1.64 (3.1x Forward P/E, -11.1% operating margin), whereas YI carries 41.6/100 (SELL) at $2.51 (N/M Forward P/E, -0.4% operating margin).

  • Technical & Structure Timing Caution: CANG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6); meanwhile YI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CANG vs YI
CANG NYSE Head-to-Head Winner
Cango Inc. American Depositary Shares, each representing two (2) Class A Ordinary Shares
Services-Prepackaged Software
$1.64
+10.81% 1D
Market Cap $60.7M
TTM Revenue $557M
Forward P/E 3.1x
Beta / 30D Vol 8.01β · 222% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 55.0 Fund 51.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.6 · SMA20: $1.31 · SMA50: $2.08
YI NASDAQ
111, Inc. American Depositary Shares
Retail-Drug Stores And Proprietary Stores
$2.51
-9.99% 1D
Market Cap $24.5M
TTM Revenue $10.5B
Forward P/E N/M
Beta / 30D Vol 0.50β · 40% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 36.0 Fund 47.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.0%), weak momentum, RSI 35
RSI-14: 35.5 · SMA20: $2.91 · SMA50: $3.16

6-Pillar Scorecard Institutional Category Breakdown (CANG 3 – 2 YI)

Columns: Metric · CANG · YI
1. Valuation Multiples CANG
Forward P/E 3.1x N/M
Trailing P/E 3.1x 0.3x
PEG Ratio N/M N/M
EV / Revenue 0.2x N/M
2. Growth & Scale YI
Revenue Growth (YoY) -33.2% -28.3%
Earnings Growth (YoY) +137.3% +0.0%
TTM Revenue (USD) $557M $10.5B
Market Cap $60.7M $24.5M
3. Profitability & Quality YI
Gross Margin -5.4% 3.0%
Operating Margin -11.1% -0.4%
Net Profit Margin -107.2% -1.0%
Return on Equity (ROE) -151.0% -27.5%
4. Balance Sheet & Cash Flow CANG
Cash Generation (TTM) $71M EBITDA -$37M EBITDA
Cash Flow Margin 12.7% EBITDA Mgn -0.3% EBITDA Mgn
Net Cash / Leverage $26M Net Debt (0.16x D/E) -27.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CANG
OpEx & R&D Intensity 5.7% of Rev ($32M) 3.4% of Rev ($356M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Capital Markets Operator Medical Distribution Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CANG (4) vs YI (6)
Institutional Metric CANG YI Criterion Row Edge
Market Capitalization
Scale
$60.7M $24.5M Larger Scale CANG
Trailing P/E Ratio
Valuation
3.1x 0.3x Lower Multiple YI
Forward P/E Ratio
Valuation
3.1x N/M Lower Multiple CANG
Revenue Growth (YoY)
Growth
-33.2% -28.3% Higher Growth YI
Operating Margin (TTM)
Profitability
-11.1% -0.4% Higher Margin YI
Net Profit Margin
Profitability
-107.2% -1.0% Higher Margin YI
Return on Equity (ROE)
Capital Efficiency
-151.0% -27.5% Higher ROE YI
52-Week Range Position
Momentum
37% ($0–$4) 0% ($2–$11) Stronger Trend CANG
Beta / 30D Volatility
Risk Regime
8.01β · 222% Vol 0.50β · 40% Vol Lower Realized Risk YI
Unified Institutional Score
Composite Signal
51.3 / 100 (HOLD) 41.6 / 100 (SELL) Higher Composite CANG
Trailing 12M Revenue (USD)
Operating Scale
$557M $10.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-5.4% 3.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$71M EBITDA ($26M Net Debt (0.16x D/E)) -$37M EBITDA (-27.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon YI +9.29 pp
CANG: -29.61% · YI: -20.32%
3M Horizon CANG +28.26 pp
CANG: +1.23% · YI: -27.03%
6M Horizon CANG +282.55 pp
CANG: +225.46% · YI: -57.09%
1Y Horizon CANG +42.13 pp
CANG: +6.49% · YI: -35.64%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CANG vs YI. Trailing 12-month operating profitability (CANG -11.1% vs YI -0.4%) and valuation multiples (CANG 3.1x vs YI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CANG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$557M
Gross Margin-5.4%
Op. Margin-11.1%
ROE / Fwd P/E-151.0% · 3.1x
YI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$10.5B
Gross Margin3.0%
Op. Margin-0.4%
ROE / Fwd P/E-27.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CANG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CANG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
YI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact YI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CANG Moat Profile Cyclical / Execution-Driven Positioning
Capital Markets Operator
Competes within the Capital Markets value chain with $60.7M market capitalization and -11.1% operating margin.
OpEx & R&D Reinvestment 5.7% of Rev ($32M)
90D Engineering Disclosures 0 Published
YI Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $24.5M market capitalization and -0.4% operating margin.
OpEx & R&D Reinvestment 3.4% of Rev ($356M)
90D Engineering Disclosures 0 Published

Investor FAQ CANG vs YI Key Questions & Quantitative Answers

As of Nov 19, 2026, Cango Inc. (CANG) is the stronger overall head-to-head candidate over 111, Inc. (YI) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). CANG carries a Unified Composite Score of 51.3/100 (HOLD) at $1.64 (3.1x Forward P/E, -11.1% operating margin), whereas YI carries 41.6/100 (SELL) at $2.51 (N/M Forward P/E, -0.4% operating margin). Technical & Structure Timing Caution: CANG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6); meanwhile YI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

YI leads the Growth & Scale pillar: CANG posts -33.2% YoY revenue growth and +137.3% YoY earnings growth on $557M TTM revenue (-5.4% gross margin, -11.1% operating margin), compared with YI at -28.3% YoY revenue growth and +0.0% YoY earnings growth on $10.5B TTM revenue (3.0% gross margin, -0.4% operating margin). On trailing 12-month operating scale, CANG generates $557M in USD-normalized revenue versus $10.5B for YI. In operating R&D and SG&A reinvestment, CANG deploys 5.7% of Rev ($32M) (0 90-day corporate R&D disclosures) versus 3.4% of Rev ($356M) (0 disclosures) for YI.

CANG screens cheaper on headline valuation multiples. CANG trades at 3.1x Forward P/E, 3.1x Trailing P/E, N/M PEG, and 0.2x EV/Revenue (12.7% EBITDA margin), whereas YI trades at N/M Forward P/E, 0.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (-0.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CANG (-151.0% ROE) versus YI (-27.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CANG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.01β · 222% Vol realized risk). By comparison, YI carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.50β · 40% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.